The FINANCIAL — Basel, June 18, 2018 Alcon, the global leader in eye care and a division of Novartis, unveils new data showing significantly improved near and intermediate distance vision with the ...

PanOptix, the first and only advanced trifocal lens for U.S. patients undergoing cataract surgery, will be showcased in educational events and clinical data presentations First-ever analyses on IOLs ...

Aging is a natural part of life, and as we grow older, our bodies go through various changes. Our hair turns gray, our joints ache a bit more and our energy levels fluctuate. But one aspect of aging ...

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that AcrySof® IQ PanOptix® Trifocal Intraocular Lens (IOL) has surpassed more than one million ...

Key findings from across the 21 scientific presentations on Alcon products will be presented at the meeting, including the soon-to-launch, first non-diffractive extended depth of focus AcrySof® IQ ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio LAS VEGAS — The PanOptix trifocal IOL ...

GENEVA--(BUSINESS WIRE)-- Alcon (ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today the introduction of Clareon ® PanOptix ® Pro intraocular lens (IOL) ...

Please provide your email address to receive an email when new articles are posted on . Patients who received the first FDA-approved trifocal IOL reported high satisfaction with the lens, but some can ...

Alcon Inc. (NYSE:ALC) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Alcon Inc. (NYSE:ALC) announced the approval of the Clareon PanOptix Pro intraocular lens for patients in ...

PanOptix, the first and only advanced trifocal lens for U.S. patients undergoing cataract surgery, will be showcased in educational events and clinical data presentations First-ever analyses on IOLs ...

“As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D—even with our leading products like PanOptix,” said Rob ...